‘Cancer-protection’ gene study reveals potential cancer drug targets
Scientists have pinpointed thousands of genetic changes in a gene that may increase a person’s risk of developing breast and ovarian cancer and also identified new potential therapeutic targets.
Researchers from the Wellcome Sanger Institute and their collaborators focused on the ‘cancer protection’ gene RAD51C, known to increase ovarian cancer risk six-fold and risk of aggressive subtypes of breast cancer four-fold.
They found over 3,000 harmful genetic changes that could potentially disrupt its function and increase cancer risk. These findings were confirmed by analysing data from large-scale health databases.
The study also identified regions of the protein essential for its function, pointing to new roles in cancer development and potential therapeutic targets.
The RAD51C gene encodes a protein crucial for DNA repair. Variants in this gene that stop the protein from working are known to increase the risk of breast and ovarian cancers and rarely, if there are two harmful gene changes are present, may result in Fanconi Anaemia, a severe genetic disorder.
Women with a faulty RAD51C gene face a 15-30% lifetime risk of developing breast cancer and a 10-15 % risk of developing ovarian cancer.
While genetic testing is common for individuals with a strong family history of cancer, the health impacts of most RAD51C variants were previously unknown.
Saturation genome editing
In this new study, researchers set out to understand the effect of 9,188 unique changes in the RAD51C gene by artificially altering the genetic code of human cells grown in a dish, in a process known as ‘saturation genome editing’.
They identified 3,094 of these variants that may disrupt the gene’s function and increase cancer risk, with an accuracy above 99.9% when compared to clinical data. Analysis of UK Biobank data and an ovarian cancer cohort of over 8,000 individuals further confirmed the link between these harmful RAD51C variants and cancer diagnoses.
By mapping the protein structure, the team also identified crucial surface areas of RAD51C essential for its DNA repair function. These regions may interact with other, yet-to-be-identified proteins or play a role in processes such as phosphorylation, offering valuable insights for drug development and potential new treatment targets.
The study also revealed the existence of ‘hypomorphic alleles’ – a type of variant that reduces the RAD51C gene’s function without completely disabling it. These appear to be more common than previously thought and may significantly contribute to breast and ovarian cancer risk.
Rebeca Olvera-León, first author of the study at the Wellcome Sanger Institute, said: “This research demonstrates that genetic risk for breast and ovarian cancer isn’t a simple yes-or-no scenario, but exists on a spectrum based on how genetic changes affect protein function. With a more comprehensive understanding of how RAD51C genetic variants contribute to cancer risk, this opens up new possibilities for more accurate risk prediction, prevention strategies, and potentially targeted therapies.”
Diana Spencer, Senior Digital Content Editor, DDW
